<DOC>
	<DOCNO>NCT00170742</DOCNO>
	<brief_summary>Phase III study compare monthly octreotide i.m . comparison additional treatment patient proliferative diabetic retinopathy lasercoagulation .</brief_summary>
	<brief_title>Study Assess Efficacy Safety Monthly Octreotide Intramuscular Injections Patients With Proliferative Diabetic Retinopathy After Lasercoagulation This Study Not Being Conducted United States .</brief_title>
	<detailed_description />
	<mesh_term>Retinal Diseases</mesh_term>
	<mesh_term>Diabetic Retinopathy</mesh_term>
	<mesh_term>Octreotide</mesh_term>
	<criteria>1 . Patients typeI typeIIdiabetes mellitus . 2 . Males female age 18 70 year . 3 . Proliferative diabetic retinopathy ( PDR ) least one eye ETDRS visual acuity score &gt; 35 letter ( 20/200 well ) , condition might interfere assessment retinopathy progression ( see exclusion criterion # 1 ) . 4 . Media clarity , pupillary dilation patient cooperation sufficient allow stereoscopic 30Â° , equivalent , fundus photograph adequate quality least one eye meet criterion # 3 . 5 . Starting photocoagulation least one eye treat PDR approximately 2 week prior start study . 6 . HbA1c &lt; 13.0 % study entry . In addition , patient must capable test blood glucose level home adjusting insulin dosage maintain blood glucose control . 7 . Systolic blood pressure &lt; 180 mm Hg diastolic blood pressure &lt; 105 mm Hg study entry . 8 . Females childbearing potential must : Have negative pregnancy test prior study entry . Be practice acceptable birth control measure inclusive intrauterine device mechanical method ( i.e. , oral contraceptive , vaginal diaphragm , vaginal sponge condom spermicide ) . 9 . Ability read , understand write German language 10 . Patients must give write informed consent participate study . 1 . Pretreatment panretinal laser treatment photocoagulation start approximately 2 week prior start study ( see inclusion criterion # 5 ) . 2 . Patients otherwise eligible eye , opinion investigator central fundus photograph reading center , condition might interfere assessment retinopathy progression , include optic atrophy , extensive heal chorioretinitis , retinopathy appear regress spontaneously ( without traction retinal detachment ) , retinal vascular occlusion , retinal degeneration , abnormality . 3 . Patients history symptomatic gallstone cholecystectomy ( patient asymptomatic cholelithiasis may enter ) . 4 . Patients brittle diabetes , typeI diabetes frequent decompensations glycemic control , recurrent ketoacidosis hypoglycemia significantly interfere lifestyle . 5 . Patients history severe hypoglycemia unawareness . 6 . Patients significant medical condition , diabetes mellitus , may interfere evaluation safety efficacy study compound ( e.g. , unstable angina pectoris , myocardial infarction within 3 month prior study entry , severe renal failure , patient renal dialysis , patient receive renal transplant ) . 7 . Patients receive investigational drug within 4 week prior study entry . 8 . Patients receive prior treatment Sandostatin somatostatin analogue . 9 . History noncompliance medical regimen consider potentially unreliable Other protocoldefined inclusion/exclusion criterion may apply .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>August 2008</verification_date>
	<keyword>Open label ,</keyword>
	<keyword>phase III ,</keyword>
	<keyword>disease ,</keyword>
	<keyword>clinical trial ,</keyword>
	<keyword>octreotide ,</keyword>
	<keyword>proliferative diabetic retinopathy , lasercoagulation</keyword>
</DOC>